Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281771 | 0.94 | NR3C1 (0.55) | NR3C1 | |
| SCHEMBL4273703 | 0.88 | NR3C1 (0.48) | NR3C1MAP4K1 | |
| SCHEMBL4283135 | 0.87 | NR3C1 (0.45) | NR3C1MAP4K1 | |
| SCHEMBL4277601 | 0.85 | NR3C1 (0.45) | NR3C1MAP4K1 | |
| SCHEMBL4280464 | 0.85 | NR3C1 (0.56) | NR3C1MAP4K1 | |
| SCHEMBL4277662 | 0.85 | NR3C1 (0.53) | NR3C1 | |
| SCHEMBL14606301 | 0.85 | NR3C1 (0.49) | NR3C1MAP4K1 | |
| SCHEMBL4278350 | 0.85 | NR3C1 (0.49) | NR3C1MAP4K1 | |
| SCHEMBL4280003 | 0.85 | NR3C1 (0.49) | NR3C1MAP4K1 | |
| SCHEMBL4276195 | 0.85 | NR3C1 (0.56) | NR3C1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | claimed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885MAP4K1 1035/4885KDM4E 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.